XORTX Therapeutics Inc (DE:ANU)
FRANKFURT:ANU
ANU Stock Chart & Stats
€0.40
-€0.05(-3.54%)
At close: 4:00 PM EST
€0.40
-€0.05(-3.54%)
Day’s Range― - ―
52-Week Range€1.10 - €4.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)213.00
Market Cap
€2.45M
Enterprise Value€402.49K
Total Cash (Recent Filing)€250.45K
Total Debt (Recent Filing)€15.07K
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,392,444
10 Day Avg. Volume640
30 Day Avg. Volume213
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)€2.02M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low debt reduces financial risk and preserves optionality for a clinical-stage biotech. With minimal fixed obligations the company can prioritize R&D spending, negotiate partnerships from a position of stability, and avoid near-term refinancing pressure that could constrain operations.
Improving Loss TrendA sustained reduction in operating losses signals improved cost discipline and more efficient use of capital. This structural improvement increases the probability that future funding will be used to advance clinical programs rather than plug escalating burn, supporting a clearer path toward reaching proof-of-concept milestones.
Focused Clinical-Stage PipelineA narrowly focused pipeline targeting hyperuricemia and kidney disease concentrates scientific expertise and aligns the company with a defined clinical and regulatory pathway. This focus improves resource allocation, makes partnering more straightforward, and targets a chronic structural healthcare need with durable market relevance.
Bears Say
No RevenueAs a development-stage biotech with no product revenues, the company lacks internal cash generation and must rely on external capital to fund operations. Persistent net losses mean continued financing needs, raising execution risk if clinical timelines slip or capital markets tighten over the medium term.
Persistent Cash BurnOngoing negative operating and free cash flow erodes runway and forces recurring financings, which can dilute shareholders and divert management attention. Without a clear near-term revenue or licensing event, continued cash burn is a durable constraint on strategic flexibility and long-term self-sufficiency.
Shrinking Equity BaseA materially reduced equity base reflects accumulated losses and likely past dilution, leaving a thinner capital cushion to absorb setbacks. This structural weakening increases reliance on new capital rounds and heightens vulnerability to adverse trial outcomes or delays, raising long-term execution risk.
XORTX Therapeutics Inc News
ANU FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was €1.09 and its highest was €4.10 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is €2.45M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 68 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -€0.503 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.503.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,392,444 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -€0.503 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:ANU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---